Journal
VACCINE
Volume 26, Issue 51, Pages 6678-6684Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.006
Keywords
SARS; Modified Vaccinia virus Ankara; Adjuvant; Mucosal immunization; Prime boost
Categories
Funding
- Bayerische Forschungsstiftung [PIZ 26/03]
- Friedrich-Schiedel-Stiftung of the Technical University Munich [5110095 TG 04]
Ask authors/readers for more resources
Severe acute respiratory syndrome (SARS) is a Serious infectious disease Caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based oil the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in pruning with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route. (C) 2008 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available